What question did this study set out to answer?

To develop covalent inhibitors targeting bacterial histidine kinases as a novel treatment strategy against antimicrobial resistance.

February 14, 2026

Development of Covalent Inhibitors for Bacterial Histidine Kinases

Key Points

To develop covalent inhibitors targeting bacterial histidine kinases as a novel treatment strategy against antimicrobial resistance.
Synthesized 2-aminobenzothiazole sulfonyl fluoride analogs
Conducted in vitro assays to evaluate inhibitor efficacy
Performed in cellulo assays for effectiveness in biological systems
Identified strong lead inhibitors for bacterial histidine kinases
Validated the potential of antivirulence therapies against antimicrobial resistance
Demonstrated successful inhibition of kinases in vitro and in cellulo

Abstract

Antivirulence therapies offer an alternative strategy against antimicrobial resistance. We synthesized 2-aminobenzothiazole sulfonyl fluoride analogs for covalent histidine kinase inhibition. In vitro and in cellulo assays also identified lead inhibitors...

Bookmark

View Full Paper